Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiyo Yakuhin Recalls Tetipline Due to Adverse Reactions
February 22, 2010
- Toho to Enhance Pharmacy Business by Acquiring Medical Brain
February 22, 2010
- BI to Make SSP Wholly-Owned Subsidiary
February 22, 2010
- Korosho's Proposal Regarding Generics Priced
February 22, 2010
- More Switch OTC Drugs Are Necessary to Stimulate Market: Mr Konja
February 22, 2010
- \170 Premium to Be Paid If Generics Dispensing Rate Exceeds 30%
February 22, 2010
- SSP: Sales Down Despite Good Sales of CHC Products
February 22, 2010
- Medical Fee Determination Process Needs to Be Revised: Mr Nagatsuma
February 22, 2010
- Take Comprehensive Measures to Prevent VTE Including Use of Anticoagulants: Dr Sakon
February 22, 2010
- JPA Concerned about Confusion among Pharmacists Regarding Three-Tiered Premiums
February 22, 2010
- Adcirca Useful for PAH with Low Incidence of ADRs: Prof. Sato
February 22, 2010
- 1st Meeting Held by Panel on Unapproved Drugs with Unmet Medical Need
February 22, 2010
- Healthcare Is Opportunity for Investment: Mr Wachi
February 22, 2010
- Doctors Assess MRs Based on Their Expertise
February 22, 2010
- DPJ Lawmaker Calls For Promotion of Pharma Industry
February 22, 2010
- FUJIFILM Embarks on Generics Business Aiming at ¥50.0 Bil. Sales in FY2014
February 22, 2010
- Novartis' Sales Up 8.2% in 2009 Driven by Diovan, Glivec
February 22, 2010
- Cost Necessary to Revitalize Healthcare Estimated by a Team: Dr Adachi
February 22, 2010
- GSK's Sales Up 22% in Japan
February 22, 2010
- 9 New Drugs to Be Reviewed on February 26
February 22, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…